The case for complement component 5 as a target in neurodegenerative disease.
Expert Opin Ther Targets
; 27(2): 97-109, 2023 02.
Article
in En
| MEDLINE
| ID: mdl-36786123
ABSTRACT
INTRODUCTION:
Complement-based drug discovery is undergoing a renaissance, empowered by new advances in structural biology, complement biology and drug development. Certain components of the complement pathway, particularly C1q and C3, have been extensively studied in the context of neurodegenerative disease, and established as key therapeutic targets. C5 also has huge therapeutic potential in this arena, with its druggability clearly demonstrated by the success of C5-inhibitor eculizumab. AREAS COVERED We will discuss the evidence supporting C5 as a target in neurodegenerative disease, along with the current progress in developing different classes of C5 inhibitors and the gaps in knowledge that will help progress in the field. EXPERT OPINION Validation of C5 as a therapeutic target for neurodegenerative disease would represent a major step forward for complement therapeutics research and has the potential to furnish disease-modifying drugs for millions of patients suffering worldwide. Key hurdles that need to be overcome for this to be achieved are understanding how C5a and C5b should be targeted to bring therapeutic benefit and demonstrating the ability to target C5 without creating vulnerability to infection in patients. This requires greater biological elucidation of its precise role in disease pathogenesis, supported by better chemical/biological tools.Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Complement C5
/
Neurodegenerative Diseases
Limits:
Humans
Language:
En
Journal:
Expert Opin Ther Targets
Journal subject:
TERAPEUTICA
Year:
2023
Type:
Article
Affiliation country:
United kingdom